Zhaoke Ophthalmology Limited

SEHK:6622 Stock Report

Market Cap: HK$704.5m

Zhaoke Ophthalmology Management

Management criteria checks 3/4

Zhaoke Ophthalmology's CEO is Benjamin Li, appointed in Jan 2017, has a tenure of 7.92 years. total yearly compensation is CN¥17.35M, comprised of 40.2% salary and 59.8% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth HK$215.02K. The average tenure of the management team and the board of directors is 3.7 years and 3.8 years respectively.

Key information

Benjamin Li

Chief executive officer

CN¥17.4m

Total compensation

CEO salary percentage40.2%
CEO tenure7.9yrs
CEO ownership0.03%
Management average tenure3.7yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Benjamin Li's remuneration changed compared to Zhaoke Ophthalmology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥227m

Mar 31 2024n/an/a

-CN¥306m

Dec 31 2023CN¥17mCN¥7m

-CN¥385m

Sep 30 2023n/an/a

-CN¥433m

Jun 30 2023n/an/a

-CN¥480m

Mar 31 2023n/an/a

-CN¥444m

Dec 31 2022CN¥21mCN¥6m

-CN¥407m

Sep 30 2022n/an/a

-CN¥355m

Jun 30 2022n/an/a

-CN¥303m

Mar 31 2022n/an/a

-CN¥1b

Dec 31 2021CN¥39mCN¥6m

-CN¥2b

Sep 30 2021n/an/a

-CN¥2b

Jun 30 2021n/an/a

-CN¥3b

Mar 31 2021n/an/a

-CN¥2b

Dec 31 2020CN¥3mn/a

-CN¥727m

Compensation vs Market: Benjamin's total compensation ($USD2.38M) is above average for companies of similar size in the Hong Kong market ($USD230.70K).

Compensation vs Earnings: Benjamin's compensation has been consistent with company performance over the past year.

CEO

Benjamin Li (61 yo)

7.9yrs

Tenure

CN¥17,354,000

Compensation

Dr. Xiaoyi Li, also known as Benjamin, Ph.D. is Founder of Lee's Pharmaceutical Holdings Limited and serves as its Executive Director & Senior Adviser since April 29, 2021. He serves as the Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Xiaoyi Li
Chairman of the Board & CEO7.9yrsCN¥17.35m0.031%
HK$ 215.0k
Xiangrong Dai
COO & Executive Directorless than a yearCN¥1.82mno data
Lit Fui Lau
President & Chief Scientific Officer5.7yrsno datano data
Yang Lei
Group General Counsel3.2yrsno datano data
Mauro Bove
Senior Vice President of Corporate Development5.9yrsno datano data
Jiang Feng
Senior Vice President of Sales & Marketing2.9yrsno datano data
Albert Tsai
Chief Medical Officer3.5yrsno datano data
Guohui Zhang
Senior Vice President of Manufacturing & Logistics2.9yrsno datano data
Carol Liu
Group Head of Regulatory Affairs3.9yrsno datano data
Suk Yan Yau
VP of Financial Dept. & Company Secretary5.3yrsno datano data

3.7yrs

Average Tenure

49yo

Average Age

Experienced Management: 6622's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Xiaoyi Li
Chairman of the Board & CEO7.9yrsCN¥17.35m0.031%
HK$ 215.0k
Xiangrong Dai
COO & Executive Director4.2yrsCN¥1.82mno data
Yuk Lam Lo
Independent Non-Executive Director3.7yrsCN¥422.00kno data
Hin Wing Wong
Independent Non-Executive Director3.7yrsCN¥422.00kno data
Tiantian Zhang
Non Executive Director3.8yrsCN¥422.00kno data
Fui Kiang Liew
Independent Non-Executive Director2.5yrsCN¥422.00kno data
Leelalertsuphakun Wanee
Non-Executive Director7.8yrsCN¥422.00k0.0043%
HK$ 30.4k

3.8yrs

Average Tenure

61yo

Average Age

Experienced Board: 6622's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:27
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhaoke Ophthalmology Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
Yue-Kwong LuiJefferies LLC